Esophageal Cancer Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

Esophageal Cancer Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Esophageal Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Esophageal Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Esophageal Cancer Market. 

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Esophageal Cancer Pipeline Analysis

Esophageal Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Esophageal Cancer and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Esophageal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

The Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as –

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal


Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule


Mechanism of Action of the Emerging Pipeline Therapies –

  • Cell death stimulants

  • Immunostimulants

  • TIGIT protein inhibitors

  • Programmed cell death-1 ligand-1 inhibitors

  • Antibody-dependent cell cytotoxicity

  • Tubulin inhibitors

  • T lymphocyte stimulants

  • Prostaglandin E EP4 receptor antagonists


Learn How the Ongoing Clinical & Commercial Activities will Affect the Esophageal Cancer Therapeutic Segment @

Esophageal Cancer Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Esophageal Cancer. Currently, Seagen is leading the therapeutics market with its Esophageal Cancer drug candidates in the most advanced stage of clinical development.

The Leading Companies in the  Esophageal Cancer Therapeutics Market Include

Adaptimmune, Adlai Nortye, Amgen, Apexigen, Inc., Ascentage Pharma Group Inc., AstraZeneca, BeiGene, CSPC ZhongQi Pharmaceutical Technology, Eli Lilly and Company, EMD Serono, Genentech, HaiHe Biopharma, Highlight Therapeutics, ImmunoFrontier, Inc, Innovent Biologics (Suzhou) Co. Ltd., Jacobio Pharmaceuticals Co., Ltd., Janssen Pharmaceuticals, Jiangsu Hengrui Medicine, Lumicell, Luye Pharma, Merck KGaA, Novartis, Oncolys Biopharma, Pfizer, Seagen, Shenzhen Hornetcorn Biotechnology, TESARO, and many others.

Esophageal Cancer Therapies Covered in the Report Include:

  • Amivantamab: Genmab

  • AN-0025: Adlai Nortye Biopharma

  • APX 005M: Apexigen

  • CDR404: CDR-Life Inc.

  • CS1001: CStone Pharmaceuticals

  • M1231: Merck KGaA

  • S-588410: Shionogi

  • Sotigalimab: Apexigen

  • Tucatinib: Seagen

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Esophageal Cancer Current Treatment Patterns

4. Esophageal Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Esophageal Cancer Late-Stage Products (Phase-III)

7. Esophageal Cancer Mid-Stage Products (Phase-II)

8. Esophageal Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Esophageal Cancer Discontinued Products

13. Esophageal Cancer Product Profiles

14. Key Companies in the Esophageal Cancer Market

15. Key Products in the Esophageal Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Esophageal Cancer Unmet Needs

18. Esophageal Cancer Future Perspectives

19. Esophageal Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States